Is Tirzepatide the Same as Mounjaro? One Drug, Three Names
Is tirzepatide the same as Mounjaro? Yes, it is. Mounjaro is a brand name, and tirzepatide is the medicine inside it, as well as inside a second brand, Zepbound. So one drug carries three names: one generic name and two brand names, both from Eli Lilly.
This page answers a naming question: how one generic name relates to its brand names, and what the official records prove. It is not a product comparison of the two brands. It walks through the FDA records: how one molecule came to have two US labels, what each label covers as of 20 November 2026, and why Europe sells it under one name.
On this page
What are the three names for tirzepatide?
One generic name and two brand names. Tirzepatide is the generic name, and both FDA labels print it in parentheses after the brand. FDA also calls tirzepatide the active ingredient, and it calls Mounjaro and Zepbound trade names. Think of one song released on two albums: the music is the same, the cover is not.
| Name | What kind of name | Whose | FDA record |
|---|---|---|---|
| Tirzepatide | Generic name, which FDA calls the active ingredient | The molecule itself, in both brands | Printed in parentheses on both US labels |
| Mounjaro | Brand name, which FDA calls a trade name | Eli Lilly | NDA 215866, won FDA approval 13 May 2022 |
| Zepbound | Brand name, which FDA calls a trade name | Eli Lilly | NDA 217806, won FDA approval 8 November 2023 |
When Zepbound won FDA approval in November 2023, the FDA news release said the active ingredient was already approved under the trade name Mounjaro. Both are prescription medicines, and as of 20 November 2026 openFDA lists only these two tirzepatide applications, each with Eli Lilly as the sponsor.
Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); FDA news release on Zepbound, 8 Nov 2023; Tirzepatide applications, Drugs@FDA (openFDA)
How do we know it is the same molecule?
The two labels describe it in matching terms, and FDA gives it one substance code. Picture one key, cut once, then hung on two keyrings with different name tags. Here is what the records show, side by side.
| Check | What the records say |
|---|---|
| Chemical description | Word for word the same in both labels: built on the GIP sequence, with Aib at positions 2 and 13 and a fatty side chain at lysine 20 |
| Molecular weight | 4,813.53 Da in both labels |
| Formula | C225H348N48O68 in both labels |
| FDA substance code (UNII) | OYN3CCI6QE for the tirzepatide in both brands |
This page stays with names and records. What the molecule does in the body is on our episode page about how tirzepatide works.
Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed)
How did one molecule end up with two US names?
Through two separate FDA applications, years apart. On 13 May 2022, Mounjaro won FDA approval to help adults who have type 2 diabetes control their blood sugar, alongside diet and exercise. FDA classed it as a new molecular entity, meaning tirzepatide was a new molecule then. Weight fell more than with the comparison drugs in those trials, yet Lilly said at launch that Mounjaro was not meant for weight loss.
Lilly says the weight approval rested on two phase 3 trials, SURMOUNT-1 and SURMOUNT-2. In SURMOUNT-1, 2,539 adults without diabetes got tirzepatide or placebo for 72 weeks, and average weight change ran from about 15 to 21 percent down in the three tirzepatide groups, against about 3 percent on placebo. Those are trial averages, not a promise for any one person.
On 8 November 2023, the same molecule won FDA approval again, as Zepbound, for chronic weight management. FDA classed that first Zepbound application as Type 10: a new use filed as its own application and not folded into Mounjaro's. That is how one molecule came to carry two US brand names, each with its own application and label.
What FDA records do not show is why Lilly chose a second name. No primary source we opened gives that reason, so this page does not guess at one.
Sources: FDA bulletin on Mounjaro, 13 May 2022; Tirzepatide applications, Drugs@FDA (openFDA); Lilly news release on Mounjaro, May 2022; Lilly news release on Zepbound, Nov 2023; SURMOUNT-1, NEJM 2022 (PMID 35658024); FDA news release on Zepbound, 8 Nov 2023
Does Europe use the Zepbound name?
No. The European Medicines Agency lists one tirzepatide brand, Mounjaro, which received EU-wide authorisation on 15 September 2022. In the EU, Mounjaro is used for type 2 diabetes and also, with diet and physical activity, to help adults lose weight and keep it off. EMA records hold no product called Zepbound.
So the second name is a US story. Someone reading a European leaflet for Mounjaro may see a weight use that the US Mounjaro label does not have.
Sources: EMA overview of Mounjaro
How have the two labels changed since 2022?
Each brand has gained uses on its own file, and the two lists still do not overlap. An indication is a use written on a drug's label, a bit like the list of doors printed on each keyring's tag. This timeline shows when each record changed, as of 20 November 2026.
| Date | Record | What changed |
|---|---|---|
| 13 May 2022 | Mounjaro, NDA 215866 | First approval, for type 2 diabetes blood sugar control in adults. FDA classed tirzepatide as a new molecular entity |
| 15 Sep 2022 | Mounjaro, EU | EU-wide authorisation. As of the August 2026 EMA overview, this one brand covers type 2 diabetes and weight management |
| 8 Nov 2023 | Zepbound, NDA 217806 | First approval, for chronic weight management. FDA classed it Type 10, a new use filed as its own application |
| 20 Dec 2024 | Zepbound | Obstructive sleep apnea in adults with obesity added |
| Dec 2025 | Mounjaro | Children 10 and older with type 2 diabetes added |
| Aug 2026 | Mounjaro | Heart attack, stroke and heart death risk use added, for adults with type 2 diabetes at high heart risk |
The Mounjaro heart use rests on SURPASS-CVOT, a human trial of 13,299 people with type 2 diabetes and heart disease. It compared Mounjaro with Trulicity, an older Lilly diabetes drug. For heart attack, stroke or heart death counted together, Mounjaro was non-inferior to Trulicity, meaning not worse by a set margin, but it was not shown to be better.
Today the Mounjaro label lists no weight loss use, and Zepbound is not approved for children. In its sleep apnea release, FDA described Zepbound as the first drug option for certain people with that condition.
Sources: Tirzepatide applications, Drugs@FDA (openFDA); Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Lilly news release on the heart risk approval, 2026; Trulicity records, Drugs@FDA (openFDA); FDA news release on sleep apnea, 20 Dec 2024; EMA overview of Mounjaro
What else do people ask about tirzepatide and Mounjaro?
Is tirzepatide the same as Mounjaro?+
Yes, they are one medicine. Tirzepatide is the generic name of what is inside Mounjaro. Mounjaro is the brand name Eli Lilly uses for it in the US for type 2 diabetes and heart event risk.
Is Zepbound the same drug as Mounjaro?+
Same molecule, different label. Both contain tirzepatide, and both US labels give it the same chemical description, weight and formula. Each brand has its own FDA application and its own approved uses.
Why does tirzepatide have two brand names in the US?+
FDA records show how, not why. FDA classed the first Zepbound application as Type 10, a new use filed as its own application rather than added to Mounjaro. The records do not give the reason Lilly chose a second name.
Is Mounjaro approved for weight loss?+
Not in the US. As of 20 November 2026, the Mounjaro label lists no weight loss use. Weight reduction is on the Zepbound label. In the EU, the one brand Mounjaro covers both type 2 diabetes and weight management.
Who makes tirzepatide?+
Eli Lilly. As of 20 November 2026, openFDA lists exactly two tirzepatide applications, Mounjaro and Zepbound, and Eli Lilly is the sponsor of both.
Do Mounjaro and Zepbound share the same warning?+
Yes. Both labels carry a boxed warning that tirzepatide caused thyroid C-cell tumors in rats, and both say it is unknown whether this happens in humans. They list the same reasons not to use it.
Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Tirzepatide applications, Drugs@FDA (openFDA); EMA overview of Mounjaro
So is tirzepatide the same as Mounjaro?
Yes, by every record above. It is one molecule sold under two US brand names, both from Eli Lilly. The Mounjaro label covers type 2 diabetes and heart event risk in some high risk adults with it. The Zepbound label covers weight reduction and sleep apnea. In Europe, the one brand is Mounjaro.
The Molecule Mechanics channel explains molecules in short animated episodes, and lists its sources under each one. We checked the two US labels, Drugs@FDA, the FDA and EMA pages, the Lilly releases and the SURMOUNT-1 report on 20 November 2026, as our medical review policy asks.
Spotted an error? Our corrections policy says how to report it.
Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Tirzepatide applications, Drugs@FDA (openFDA); EMA overview of Mounjaro
This page is about names and regulatory records only, and it gives no advice. Each section lists the records it used at its end.